SIOP-E HR-MBL Hungarian Proposal

Slides:

Advertisements

Similar presentations

13th Annual Hematology & Breast Cancer Update Update in Lymphoma

Advertisements

CI - 1 Cure Rate Models and Adjuvant Trial Design for ECOG Melanoma Studies in the Past, Present, and Future Joseph Ibrahim, PhD Harvard School of Public.

Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

NPC Treatment Outcomes: Disease Control and Failure Patterns Sandeep Samant, MS, FRCS.

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Supplementary Figure 1. Outline of the MRC UKALL 2003 trial protocol detailing drugs used and timing schedules for the three regimens. Patients were allocated.

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

Volume 140, Issue 1, Pages (July 2011)

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

1 Stone RM et al. Proc ASH 2015;Abstract 6.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Table 1. Patient Characteristics

Maury S et al. Proc ASH 2015;Abstract 1.

Platzbecker U et al. Proc ASH 2014;Abstract 12.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Director Department of Pediatric Hematology & Oncology Delhi, INDIA.

Volume 55, Issue 3, Pages (May 2010)

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

Building better therapy for children with acute lymphoblastic leukemia

Stephen Ansell, MD, PhD Mayo Clinic

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Survival Outcomes at 3 Years

Volume 14, Issue 3, Pages (March 2013)

Nat. Rev. Urol. doi: /nrurol

Angiogenesis Inhibitors

Untch M et al. Proc SABCS 2010;Abstract P

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,

Stephen Ansell, MD, PhD Mayo Clinic

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

ARRAY The MILO Study Study Design Schema

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Grövdal M et al. Blood 2008;112:Abstract 223.

Volume 386, Issue 9999, Pages (September 2015)

Table 2. Progression-Free Survival

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Suppl Table 1. Database has been randomly split in two groups

Risk factors for mortality and failure of conservative treatment after aortic type B dissection Jochen Grommes, MD, Andreas Greiner, MD, Bianca Bendermacher,

Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Supplementary Figure 2 Shiota et al.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Outcome after surgery for prosthetic valve endocarditis and the impact of preoperative treatment Herko Grubitzsch, MD, PhD, Andreas Schaefer, Christoph.

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Supplementary Figure 2A

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Nat. Rev. Urol. doi: /nrurol

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Donor Cell Leukemia: A Review

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective.

Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial Nasser.

High volume Low volume HORRAD STAMPEDE Failure-free survival

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001.

Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Uncovering the Right Sequence

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

SIOP-E HR-MBL Hungarian Proposal Miklós Garami, MD. PhD. National Coordinator 5th November, 2013 Amsterdam, The Netherlands

Active Treatment Maintenance Therapy Include ABMT th. in HR-MBL group. We observed increased OS and EFS. Maintenance Therapy Relapses remain a problem especially in high risk MBL patients. We observed most relapses during the 2. year after the beginning of chemotherapy.

Maintenance Therapy Metronomic th. (in the 1. yr after active tr.) topotecan / topoisomerase inhibitor vincristine / vinca alkaloid thalidomide / angiogenesis inhibitor calcitriol / vitamin D3 Supplementary tr. (in the 2. yr after active tr.) calcitriol / vitamin D3 astaxanthin / carotenoid celecoxib / COX-2 inhibitor, NSAID

Overall Survival of Low (LR) - and High Risk (HR) Patients 2004-2012 93,8% at 5 yrs 56,5% at 5 yrs Figure 3.A

Event-free Survival of Low (LR) - and High Risk (HR) Patients 2004-2012 86,2% at 5 yrs 41,5% at 5 yrs Figure 3.B

Number of Relapses (2007-2001) Figure 4.

Overall Survival (OS) Rates Comparison Treatment Periods: 2004-2006 and 2007-2012 Figure 5.A

Event-Free Survival (EFS) Rates Comparison Treatment Periods: 2004-2006 and 2007-2012 Figure 5.B